H. Lundbeck A/S
HLUN-A
Rangering i aksjer
#2988
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Aksjekurs
$7.41
Markedsverdi
$6.17B
Endring (1 dag)
3.44%
Endring (1 år)
33.63%
Land
DK
Handel H. Lundbeck A/S (HLUN-A)
Kategori
Healthcare
Utbyttehistorikk for H. Lundbeck A/S (HLUN-A)
H. Lundbeck A/S (aksjesymbol: HLUN-A) har gitt totalt 4 utbyttebetalinger.
Summen av alle utbytter (justert for aksjesplitt): $3.38
Utbytteavkastning (TTM): 0.0242
Summen av alle utbytter (justert for aksjesplitt): $3.38
Utbytteavkastning (TTM): 0.0242
Utbyttebetalinger for H. Lundbeck A/S (HLUN-A) fra 2023 til 2026
Årlige utbyttebetalinger
| År | Utbytte (justert for aksjesplitt) | Endre |
|---|---|---|
| 2026 (TTM) | $1.15 | 21.05% |
| 2025 | $0.95 | 35.71% |
| 2024 | $0.7 | 20.69% |
| 2023 | $0.58 | 0.00% |
Liste over alle utbyttebetalinger
| År | Utbytte | Endre |
|---|---|---|
| 2026 (TTM) | $1.15 | 21.05% |
| 2025 | $0.95 | 35.71% |
| 2024 | $0.7 | 20.69% |
| 2023 | $0.58 | 0.00% |
Utbyttebetalinger for lignende selskaper eller konkurrenter
| Selskap | Antall utbyttebetalinger | Land |
|---|---|---|
| 23.00% |
US
|
|
| 0.00% |
SE
|
|
| 0.00% |
FR
|
|
| 0.00% |
IT
|
|
| 0.00% |
US
|
